Last reviewed · How we verify
Tremelimumab (Regimen 1)
Tremelimumab is a monoclonal antibody that targets CTLA-4, a protein that helps regulate the immune system.
Tremelimumab is a monoclonal antibody that targets CTLA-4, a protein that helps regulate the immune system. Used for Metastatic melanoma, Non-small cell lung cancer.
At a glance
| Generic name | Tremelimumab (Regimen 1) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to CTLA-4, tremelimumab blocks its interaction with B7-1 and B7-2, leading to increased T-cell activation and proliferation. This can enhance the body's immune response against cancer cells. However, this also increases the risk of autoimmune reactions.
Approved indications
- Metastatic melanoma
- Non-small cell lung cancer
Common side effects
- Fatigue
- Rash
- Diarrhea
- Nausea
- Vomiting
- Hypertension
- Hypothyroidism
- Hyperthyroidism
- Pneumonitis
- Colitis
Key clinical trials
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (PHASE1)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (PHASE2)
- BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma (PHASE1, PHASE2)
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma (PHASE2, PHASE3)
- Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (PHASE3)
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer (PHASE2)
- A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tremelimumab (Regimen 1) CI brief — competitive landscape report
- Tremelimumab (Regimen 1) updates RSS · CI watch RSS
- AstraZeneca portfolio CI